NCT00632463已完成2 期
RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 21
- 试验地点
- 38
- 主要终点
- Circulating RI-001 Titer
研究概览
简要总结
RSV infections can develop into serious, life threatening conditions among immunocompromised patients. The objective of this study (ADMA 001) is to evaluate the safety and efficacy of RI-001 for the prevention of lower respiratory tract infections in immunocompromised patients identified as being infected with RSV in the upper respiratory tract.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 2 Years 至 65 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •An IEC/IRB approved written informed consent signed and dated by the patient or by parent(s) or a legally acceptable representative. The consent form or a specific assent form, where required, will be signed and dated by minors.
- •Documented Bone Marrow Transplant (BMT)/Hematopoietic Stem Cell Transplant (HSCT), Pulmonary/Cardiac Transplant, Pulmonary Transplant or Liver Transplant within the 2 years prior to randomization to the study drug.
- •Male/Female patients age: (Pediatric) ≥2 years and <16 years at the time of informed consent.
- •Male/Female patients age: (Adult) ≥ 16 years and ≤ 65 years at the time of informed consent.
- •Patient must have an URTI as defined by Respiratory Assessment Score (RAS)=
- •Patients must be actively taking at least one immunosuppressive agent.
- •Patients must have a positive RSV RT-PCR at the time of the randomization procedures.
- •Female patients must be of non-childbearing potential or have a negative pregnancy test prior to study start and be deemed not at risk of becoming pregnant by adherence to a reliable contraceptive method for the duration of the study. Females of non-childbearing potential are defined as women who have had a hysterectomy, bilateral oophorectomy, tubal ligation or who have been post-menopausal for at least two years, or are considered to be sterile due to recent chemotherapy.
- •Female patients who are not breast-feeding.
- •Patient/legally acceptable representative considered as reliable and capable of adhering to the protocol (e.g. able to understand and complete diaries and questionnaires), visit schedules or treatment regimen according to the judgment of the Investigator.
排除标准
- •Documented RSV lower respiratory tract infection (respiratory assessment score is greater than 1) as determined by the site investigators or research staff.
- •Requirement for mechanical ventilation, extracorporeal membrane oxygenation, continuous positive airway pressure or other mechanical respiratory or cardiac support
- •Unstable respiratory status so severe that survival is not expected for longer than 6 months.
- •End organ dysfunction resulting in anticipated survival of less than 6 months.
- •Known to be HIV positive.
- •Administration of any RSV specific products, including palivizumab (Synagis®) in the 3 months prior to randomization procedures.
- •Previous, current, or planned administration of an investigational RSV vaccine.
- •Known hypersensitivity to immunoglobulin.
- •Known Immunoglobulin (IgA) deficiency
- •Known renal impairment requiring any form of dialysis (HD, PD, CRRT).
- •Known hemodynamically significant congenital heart disease.
- •Previous poor compliance with visit schedules.
- •Severe medical, neurological or psychiatric disorders or laboratory values which may have an impact on the safety of the patient.
- •Concurrent participation in other investigational drug product studies; any exception must be approved by the ADMA Biologics Medical Director.
结局指标
主要结局
Circulating RI-001 Titer
时间窗: Study day 18
The primary endpoint of this study was the mean fold titer increase from baseline to Day 18 in circulating serum anti-RSV neutralizing antibody following treatment with RI-001.
次要结局
- Incidence of RSV Progression From Symptomatic Upper Respiratory Tract Infection to Lower Respiratory Tract Infection.(Study day 33)
- The Number of Patients Achieving at Least a 4-fold Increase in Serum RSV Neutralizing Antibody Titers(18 Days)
研究者
研究点 (38)
Loading locations...
相似试验
已完成
不适用
RSV Observational Study 2Respiratory Syncytial Virus InfectionsNCT01922648University of Oxford35
已完成
不适用
Immune Response to Respiratory Syncytial Virus (RSV) in Health Care WorkersHealthyNCT01563692University of Oxford30
已完成
1 期
Respiratory Syncytial Virus Human Challenge in Healthy Adult VolunteersUpper Respiratory Tract InfectionNCT02484417National Institute of Allergy and Infectious Diseases (NIAID)32
Unknown
不适用
Assess the Correlation With Severe Respiratory Syncytial Virus Disease in the First 6 Months in Children With Congenital Heart Disease and Maternal Ac-AntiVSR Titers During PregnancyRespiratory Syncytial Virus, Congenital Heart DiseaseNCT04734782Hospital Angeles Lomas60
撤回
不适用
The effect of severe respiratory syncytial virus (RSV) lower respiratory tract infections in mechanically ventilated infants younger than 12 months of age on recurrent wheezing and lung functiobronchiolitis/pneumoniaRSV lower respiratory tract infection10024970NL-OMON34923niversitair Medisch Centrum Groningen70